Mirvetuximab Chemical Properties

form 

Liquid

color 

Colorless to light yellow

Mirvetuximab Usage And Synthesis

Uses

Mirvetuximab (M9346A) is an anti-FOLR1 (folate receptor 1) monoclonal antibody. Mirvetuximab is the antibody moiety of folate receptor alpha (FRα)-targeting ADC (Mirvetuximab soravtansine). Mirvetuximab soravtansine can be used in ovarian and other FRα-positive cancer research[1][2][3].

References

[1] Moore KN, et al. Safety and Activity of Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha-Targeting Antibody-Drug Conjugate, in Platinum-Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer: A Phase I Expansion Study. J Clin Oncol. 2017 Apr 1;35(10):1112-1118. DOI:10.1200/JCO.2016.69.9538
[2] Loebrich S, et al. Development and Characterization of a Neutralizing Anti-idiotype Antibody Against Mirvetuximab for Analysis of Clinical Samples. AAPS J. 2017 Jul;19(4):1223-1234. DOI:10.1208/s12248-017-0098-0
[3] Ab O, et al. IMGN853, a Folate Receptor-α (FRα)-Targeting Antibody-Drug Conjugate, Exhibits Potent Targeted Antitumor Activity against FRα-Expressing Tumors. Mol Cancer Ther. 2015 Jul;14(7):1605-13. DOI:10.1158/1535-7163.MCT-14-1095

Mirvetuximab(1453084-36-0)Related Product Information

• Otlertuzumab
• Lexatumumab
• Rolinsatamab
• Sotrovimab
• Daxdilimab
• Trastuzumab
• Sintilimab
• Sirukumab
• Atibuclimab
• Galcanezumab